1887

Abstract

Guinea pigs were administered antiserum 24 h (As+24) or 72 h (As+72) after intravaginal herpes simplex virus type 2 (HSV-2) challenge. Treatment at either time reduced acute virus replication in the dorsal root ganglia and the overall magnitude of replication in the genital tract. In two studies, As+24 treatment significantly reduced the severity of primary genital skin disease and the frequency of subsequent spontaneous recurrent disease. In contrast, As+72 treatment produced a modest reduction in primary disease severity but did not impact on recurrent disease. Quantitative PCR analysis of dorsal root ganglia DNA from latently infected animals showed that As+24 treatment produced a significantly reduced viral DNA burden, which appeared to correlate with the reduction in recurrent disease. The amount of DNA in the ganglia of As+72-treated animals was not significantly lower than that of controls. These observations have implications for both the dynamics of latency establishment and desirable vaccine characteristics.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-11-2797
2002-11-01
2020-07-14
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/11/0832797a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-11-2797&mimeType=html&fmt=ahah

References

  1. Bernstein D. I., Harrison C. J.. 1989; Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrobial Agents and Chemotherapy33:1511–1515
    [Google Scholar]
  2. Bernstein D. I., Stanberry L. R., Harrison C. J., Kappes J., Myers M. G.. 1986; Antibody response, recurrence pattern and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea pigs: effects of acyclovir. Journal of General Virology67:1601–1612
    [Google Scholar]
  3. Bourne N., Stanberry L. R., Bernstein D. I., Lew D.. 1996; DNA immunization against experimental genital herpes simplex virus infection. Journal of Infectious Diseases173:800–807
    [Google Scholar]
  4. Kavaliotis J., Loukou I., Trachana M., Gombakis N., Tsargaropoulou-Stigga H., Koliouskas D.. 1998; Outbreak of varicella in a pediatric oncology unit. Medical and Pediatric Oncology31:166–169
    [Google Scholar]
  5. Klein R. J.. 1980; Effect of immune serum on the establishment of herpes simplex virus infection in trigeminal ganglia of hairless mice. Journal of General Virology49:401–405
    [Google Scholar]
  6. McKendall R. R., Klassen T., Baringer J. R.. 1979; Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread. Infection and Immunity23:305–311
    [Google Scholar]
  7. Morrison L. A., Zhu L., Thebeau L. G.. 2001; Vaccine-induced serum immunoglobulin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. Journal of Virology75:1195–1204
    [Google Scholar]
  8. Oakes J. E., Rosemund-Hornbeak H.. 1978; Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection. Infection and Immunity21:489–495
    [Google Scholar]
  9. Sawyer L. A.. 2000; Antibodies for the prevention and treatment of viral diseases. Antiviral Research47:57–77
    [Google Scholar]
  10. Shimeld C. T., Hill J., Blyth W. A., Easty D. L.. 1990; Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system. Journal of General Virology71:681–687
    [Google Scholar]
  11. Snydman D. R.. 1990; Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Reviews of Infectious Diseases12 (Suppl. 7):839–847
    [Google Scholar]
  12. Stanberry L. R., Kern E. R., Richards J. T., Abbott T. M., Overall Overall. J. Jr. 1982; Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. Journal of Infectious Diseases146:397–401
    [Google Scholar]
  13. Stanberry L. R., Kern E. R., Richards J. T., Overall Overall. J. Jr. 1985; Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology24:226–231
    [Google Scholar]
  14. Stanberry L. R., Bernstein D. I., Burke R. L., Pachl C., Myers M. G.. 1987; Recombinant herpes simplex virus glycoprotein vaccine protects against initial and recurrent genital herpes. Journal of Infectious Diseases155:397–404
    [Google Scholar]
  15. Wachsman M., Kulka M., Smith C. C., Aurelian L.. 2001; A growth and latency compromised herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine19:1879–1890
    [Google Scholar]
  16. Walz M. A., Yamamoto H., Notkins A. L.. 1976; Immunologic response restricts number of cells in sensory ganglia infected with herpes simplex virus. Nature264:554–556
    [Google Scholar]
  17. Zaia J. A., Levin M. J., Preblud S. R., Leszczynski J., Wright G. G., Ellis R. J., Curtis A. C., Valerio M. A., LeGore J.. 1983; Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. Journal of Infectious Diseases147:737–743
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-11-2797
Loading
/content/journal/jgv/10.1099/0022-1317-83-11-2797
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error